Vanda Pharmaceuticals (VNDA) Receiving Somewhat Favorable Press Coverage, Analysis Finds

News articles about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6618631102513 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

A number of research analysts have commented on the stock. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies set a $23.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $21.50.

Vanda Pharmaceuticals (NASDAQ VNDA) opened at $12.95 on Wednesday. Vanda Pharmaceuticals has a one year low of $11.90 and a one year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to the consensus estimate of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. sell-side analysts anticipate that Vanda Pharmaceuticals will post -0.39 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals (VNDA) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://weekherald.com/2017/11/15/vanda-pharmaceuticals-vnda-given-media-impact-score-of-0-04.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply